Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Park, Y. H.
Right arrow Articles by Kim, H. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, Y. H.
Right arrow Articles by Kim, H. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 34:245-249 (2004)
© 2004 Foundation for Promotion of Cancer Research

Gemcitabine and Vinorelbine as Second-line Therapy for Non-small Cell Lung Cancer after Treatment with Paclitaxel plus Platinum

Yeon Hee Park, Jae Cheol Lee, Cheol Hyeon Kim, Baek-Yeol Ryoo and Heung Tae Kim+

Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea

Objective: To investigate the activity and feasibility of combination therapy of gemcitabine and vinorelbine for patients with advanced NSCLC after the failure of initial treatment with paclitaxel plus platinum.

Methods: From March 2000 to August 2002, 38 evaluable patients (median age 55 years) with NSCLC, who had failed to recover after treatment with paclitaxel plus platinum, received vinorelbine (30 mg/m2 i.v.) followed by gemcitabine (1000 mg/m2 i.v.), both being administered on days 1 and 8 and recycled every 3 weeks.

Results: Objective responses were as follows: partial response, 8/38 [21%; 95% confidence interval (CI) 8–23%]; and stable disease, 21/38 (55%). Median time to progression was 3.9 months and the median overall survival was 8.1 months. Grades III and IV neutropenia were seen in 17 and 11% of patients, respectively.

Conclusion: This combination chemotherapy with gemcitabine and vinorelbine is active and highly tolerable as a second-line therapy for NSCLC.

+ For reprints and all correspondence: Yeon Hee Park, Division of Medical Oncology, Korea Cancer Center Hospital, 215–4, Gongneung-Dong, Nowon-ku, Seoul 139-706, Korea. E-mail: yhpark{at}kcch.re.kr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.